Nanoparticles from human serum albumin (HSA) are biocompatible drug delivery agents that have been approved by the Food and Drug Administration. This study evaluated the use of HSA nanoparticles for encapsulation of both near-infrared ionic dye (IR 780) and chemotherapeutic drug for theranostics against cancer. IR 780 is a near-infrared dye has selective tumor toxicity based on the choice of anion. When illuminated with NIR laser, IR 780 dye has photothermal properties against tumor cells. When combined with the chemotherapeutic properties of anticancer drug such as doxorubicin and paclitaxel, the hybrid HSA nanoparticles with particle size of ~ 150 nm has the potential for improved therapeutic activity against tumor cells. The release of these therapeutic agents from HSA nanoparticles is achieved by the enzymatic action of metalloproteinases that are overexpressed in tumor cells and by photothermal heating under laser irradiation. This study reports the nanoparticle stability, encapsulation efficiency, and the enzymatic release of the NIR dye and drug from the HSA nanoparticles.

Hybrid human serum albumin nanoparticles co-encapsulating near infrared ionic dye and chemotherapeutic drug for theranostics

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.